Department of Internal Medicine, The Ohio State University College of Medicine, B054 Graves Hall, 333 W 10th Ave, Columbus, OH, 43210, USA,
Stem Cell Rev Rep. 2014 Dec;10(6):743-52. doi: 10.1007/s12015-014-9536-x.
The opportunity to undergo an induced pluripotent stem cell-based autologous transplant can strike patients as a chance for a cure from a debilitating condition with few options for respite. However, when clinical studies of this caliber present themselves, patients and researchers, each with their own set of motives, may find it difficult to take a balanced approach to evaluating them. We present a patient-centered risk-benefit analysis of the iPSC-based clinical research currently underway in Japan, including a survey of in vitro and in vivo tests that support this project, an in-depth discussion of risks, and further elucidation of considerations patients may wish to consider. The arguments presented will assist patients in undertaking a more informed decision-making process.
有机会接受基于诱导多能干细胞的自体移植，可能会让患者感到这是一种摆脱衰弱疾病的治愈机会，而这种疾病几乎没有缓解的选择。然而，当出现这种规模的临床研究时，患者和研究人员可能会因为各自的动机而难以采取平衡的方法来评估它们。我们对日本目前正在进行的基于 iPSC 的临床研究进行了以患者为中心的风险-效益分析，包括对支持该项目的体外和体内测试的调查、对风险的深入讨论，以及进一步阐明患者可能希望考虑的因素。提出的论点将帮助患者做出更明智的决策过程。
